C12Y 304/21109
Matriptase
Official title: Matriptase (3.4.21.109)
C12Y304/21109 (Matriptase) appears on 22 US grants and 46 published applications in this corpus.
Search patents in C12Y- Granted patents
- 22
- Published applications
- 46
- Assignees
- 23
- Inventors
- 93
- Latest grant
- 24 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 3 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 1 | 2 |
| 2010 | 2 | 1 |
| 2011 | 1 | 1 |
| 2012 | 1 | 3 |
| 2013 | 1 | 2 |
| 2014 | 1 | 1 |
| 2015 | 0 | 1 |
| 2016 | 1 | 0 |
| 2017 | 1 | 1 |
| 2018 | 0 | 2 |
| 2019 | 1 | 3 |
| 2020 | 1 | 4 |
| 2021 | 2 | 3 |
| 2022 | 2 | 2 |
| 2023 | 5 | 5 |
| 2024 | 2 | 8 |
| 2025 | 0 | 1 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use24 Dec 2024US 12,173,337 B2Vertex Pharmaceuticals Incorporated
- Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of use thereof9 Jan 2024US 11,866,710 B2Alnylam Pharmaceuticals, Inc.
- IL-15 prodrugs and methods of use thereof19 Dec 2023US 11,845,801 B2AskGene Pharma Inc.
- Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use7 Nov 2023US 11,807,882 B2Vertex Pharmaceuticals Incorporated
- Methods and compositions for diagnosing and treating diseases31 Oct 2023US 11,802,164 B2Celera Corporation
- Compounds and compositions for use in stem cell transplantation17 Sep 2026US 2026/0275350 A1New York Blood Center, Inc.
- Auto-tuning drug regulator constructions23 Apr 2026US 2026/0108617 A1
- Sirna or salt thereof and medicament for inhibiting expression of tmprss6 gene, and use thereof7 Aug 2025US 2025/0250574 A1BeBetter Med Inc.
- Protease-activated polypeptides14 Nov 2024US 2024/0376171 A1Hoffmann-La Roche Inc.
- Conditional activation of immunoglobulin molecules10 Oct 2024US 2024/0336909 A1Harpoon Therapeutics, Inc.
Most cited
By later US patents
- Protease screening methods and proteases identified thereby28US 9,290,757 B2Catalyst Biosciences, Inc. · 2016
- Protease screening methods and proteases identified thereby23US 8,211,428 B2Catalyst Biosciences, Inc. · 2012
- Protease screening methods and proteases identified thereby16US 8,663,633 B2Catalyst Biosciences, Inc. · 2014
- Mutant MT-SP1 proteases with altered substrate specificity or activity11US 7,939,304 B2Catalyst Biosciences, Inc. · 2011
- Diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof6US 7,488,813 B2Compugen Ltd. · 2009